Common Side Effects of Infusion Therapy - and How to Maximize Patient Comfort
A clinical and operational guide for healthcare teams on recognizing infusion therapy side effects, managing reactions, and building patient comfort into every session.
Remy Healthcare Team
6 min read · May 2, 2025 · Updated May 17, 2026

Infusion therapy delivers medications directly into the bloodstream for conditions that cannot be effectively managed orally - autoimmune disorders, cancers, infections, and a growing range of chronic illnesses. As biologics and immunotherapies become more common in outpatient settings, more patients are coming through infusion programs at FQHCs and community health centers that may not have years of experience managing these reactions.
Getting infusion therapy right means two things: managing clinical risk with precision, and making every session an experience patients want to return for. Both matter for outcomes. Both matter for the program's long-term viability.
Key Takeaways
- Immediate infusion reactions - flushing, chills, nausea, dizziness - are common and manageable when staff are trained to recognize them and respond early.
- Allergic reactions occur in up to 15% of patients receiving monoclonal antibody therapies. Emergency protocols and staff training are not optional.
- Delayed reactions can appear hours or days after treatment. Patient education and 24-hour follow-up protocols reduce the risk of serious complications going unaddressed.
- Cytokine release syndrome and anaphylaxis are rare but life-threatening. Every infusion site needs documented emergency procedures and staff who have practiced them.
- Patient comfort is not a luxury add-on. It directly improves treatment adherence, which affects clinical outcomes and program revenue.
The most common side effects during and after infusion
Immediate reactions
Reactions during infusion occur as medication enters the bloodstream. They vary by drug, by the patient's immune response, and by infusion technique - but the most common ones are predictable.
Immediate symptoms to watch for:
- Flushing or warmth
- Chills or shivering
- Mild fever
- Nausea or vomiting
- Headache
- Dizziness
Infusion-related allergic reactions - particularly from monoclonal antibodies and biologics - occur in up to 15% of patients, according to the American College of Rheumatology. Signs of an allergic reaction include rash or hives, shortness of breath, chest tightness, and wheezing. When those appear, the right move is immediate: stop the infusion, administer antihistamines, and escalate based on severity.
Delayed reactions
Side effects that develop hours or days after treatment are easier to miss because the patient is no longer in the chair. Common delayed effects include headaches, persistent fatigue, mild joint or muscle aches, low-grade fever, and skin rashes.
Serum sickness - a rare but significant immune response - typically appears one to two weeks after treatment and involves fever, rash, and joint pain. Patient education before discharge is the first line of defense: patients need to know what to watch for, and they need a clear path to report it.
When reactions signal serious complications
Anaphylaxis
Anaphylaxis is a severe allergic reaction that can develop within minutes. Symptoms include difficulty breathing, swelling of the face, tongue, or throat, rapid blood pressure drop, and loss of consciousness. Immediate epinephrine is critical. Every infusion site should have documented emergency protocols and staff who have practiced them - not just read them.
Cytokine release syndrome
Cytokine release syndrome (CRS) is a systemic inflammatory response most often seen with immunotherapies like CAR-T cell treatments, though it can occur with other biologics. Early signs include fever above 100.4°F, hypotension, tachycardia, and confusion. Severe cases can progress rapidly to organ failure. Monitoring must be continuous, and early supportive treatment - corticosteroids and cytokine blockers in serious cases - is essential.
Infection risk
Every infusion creates a pathway through the skin. Sterile technique minimizes infection risk, but post-infusion monitoring catches what technique does not. Patients should know to report redness or swelling at the IV site, fever within 24 to 72 hours, and pain or warmth around the insertion point. Those signs, taken seriously early, prevent outcomes far worse than the original infusion.
Managing reactions: what good preparation looks like
Before the session
Strong pre-infusion preparation is where most reactions are prevented. This means:
- Thorough patient education on possible side effects and what to do if they occur
- Pre-medications - antihistamines or corticosteroids - when clinically indicated
- Encouraging hydration the day before and on treatment day
- Meticulous review of allergy history and current medications
During the infusion
Slow, steady titration - especially for biologics - gives the body time to adjust. Vital signs and patient comfort should be monitored continuously, not just at the start and end. Emergency supplies must be immediately accessible, not in a different room or on a different floor.
When mild symptoms appear, slowing the infusion rate often resolves them. More serious cases require pausing or stopping treatment entirely. Patients are often reluctant to speak up. Never wait for them to complain.
After the session
Post-infusion care is where many programs fall short. A phone or text check-in within 24 hours is not just good patient experience - it catches delayed reactions before they escalate. Symptom diaries help patients document what they experience between sessions, which builds a clearer clinical picture over time. Clear written instructions about what symptoms require immediate medical attention close the loop.
Making comfort part of the clinical model
Patient comfort is often described as a nice-to-have. The evidence says otherwise. Research consistently shows that patients receiving ongoing biologics have better treatment adherence in comfortable, private settings. Better adherence means better clinical outcomes. For an infusion program's financial model, it also means patients who come back.
The specific touches matter:
- Warm, well-lit environments instead of sterile, fluorescent-heavy spaces
- Warm blankets to manage the chills that biologics frequently cause
- Entertainment options - TVs, Wi-Fi, reading material
- Ergonomic positioning for IV lines that accommodate long sessions
- Frequent check-ins that feel attentive rather than intrusive
- Refreshments that support hydration
None of this is expensive. All of it changes the experience.
Building patient confidence through proactive communication
Patients who understand what might happen are better partners in managing it. Open conversations before the first session - about risks, benefits, common side effects, and what to do if something feels wrong - create informed patients who are more likely to report concerns and less likely to abandon treatment.
Documenting reactions across sessions also helps identify patterns. A patient who experiences mild flushing on session three and four may benefit from a modified pre-medication protocol on session five. That kind of refinement is only possible when information is captured and reviewed rather than treated as a one-off event.
If you are building or expanding an infusion program and want to put the right clinical and operational systems in place from the start, contact Remy to talk through what a well-structured infusion model looks like.

Written by
Remy Healthcare Team
340B & FQHC Specialists
The Remy team advises FQHCs and 340B covered entities on program management, infusion operations, and revenue optimization.


